XLV, the Health Care Select Sector SPDR ETF, has completed a clean break from the defensive positioning that dominated the past six weeks — the short hedges that built so aggressively through May are now coming off, and the price has followed.
The price move is the clearest signal of the shift. XLV closed at $154.57 on June 9, up 5.6% on the week and 7.7% over the past month. That's a meaningful acceleration from the $153.01 level noted in last week's note. Healthcare has been one of the standout sector performers as macro uncertainty keeps rotation flows moving away from rate-sensitive growth names — and this week that dynamic appears to have intensified.
The unwinding of short hedges confirms the directional change. Short interest dropped 8% over the week to 3.66% of the float, around 9.5 million shares — pulling back from the plateau near 10.5 million that had persisted since mid-May. That is a genuine reversal, not noise: the one-month change is still positive at 23%, reflecting the May build, but the weekly direction has turned. Cost to borrow fell 16% on the week to just 0.36% — near the lowest reading of the past 30 days — consistent with reduced demand for borrows rather than any inventory pressure. Availability has loosened dramatically, rising 57% over the week to 832%, well clear of the 52-week low of 24%. The borrow market for this ETF is about as relaxed as it gets. The ORTEX short score, at 35.8, is near the bottom of its recent range and shows no sign of renewed bearish conviction rebuilding.
Options positioning has also normalised, though it retains a mild defensive tilt. The put/call ratio is running at 1.34, roughly in line with its 20-day average of 1.36 and effectively flat on a z-score basis at -0.07. That's a world away from the readings above 2.0 that prevailed through late April and early May. The 52-week range on the PCR spans 0.47 to 2.67 — today's reading sits in the middle third of that band, suggesting options traders are neither fearful nor complacent. Protective demand has faded with the rally.
Institutional ownership tells a supporting story. As of March 31, Managed Account Advisors added over 2.8 million shares to become the largest disclosed holder at 8.6% of shares. Goldman Sachs and its asset management arm both added shares in the same period, while JPMorgan trimmed slightly. The profile is consistent with XLV being used as a tactical defensive allocation rather than a high-conviction structural bet — flows in when risk appetite softens, trimmed as confidence returns.
What to watch next is whether the short interest decline continues toward the pre-May baseline of roughly 7.5–8 million shares, or whether fresh macro anxiety re-ignites hedge demand at current price levels — the answer will say as much about the broader risk environment as it does about healthcare specifically.
See the live data behind this article on ORTEX.
Open XLV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
